Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

By CEO.CA / July 25, 2025 / www.youtube.com / Article Link


We caught up with Dr. John Yu, CEO of Kairos Pharma, Ltd. (NYSE American: KAPA) to discuss the company's safety data ...

Recent News

Big Gold still struggling overall in 2026

September 28, 2026 / www.canadianminingreport.com

Gold stocks down on metal price pullback

September 28, 2026 / www.canadianminingreport.com

Mining sector far outpaces tech over past three years

September 21, 2026 / www.canadianminingreport.com

Gold stocks down with GDXJ outperforming on rebalancing

September 21, 2026 / www.canadianminingreport.com

Copper slides as US apparently wavering on tariff hikes

September 14, 2026 / www.canadianminingreport.com
See all >
Share to Youtube Share to Facebook Facebook Share to Linkedin Share to Twitter Twitter Share to Tiktok